ViiV broadens HIV treatment options available to paediatrics with FDA application

The North Carolina-based company aims to end paediatric HIV/AIDS by introducing new treatment options on the market.

The HIV specialists ViiV Healthcare submitted their HIV treatment for paediatrics application to the Food and Drug Administration (FDA). The treatment consists of abacavir, dolutegravir and lamivudine as a fixed dose in a tablet formulation. Additionally, the company also aims to extend the current approval of Triumeq, to decrease the minimum weight requirement at which paediatrics can be prescribed medication. This would allow for a new treatment option. There is an increased global concern with the rate of HIV infections in children, as 1.7 million children under the age of 15 years are infected by the virus. The Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that in 2020, 54% of children aged between 0-14 years had access to HIV treatment, however, leaving 850,00 without the life sustaining treatment they require.

Paediatrics are faced with multiple difficulties when it comes to their treatment. There has been a lack of accessibility to treatment and delayed onset of treatment, as evident with UNAIDS reporting that a majority of AIDs related deaths occur in children under the age of 5 years. Merdad Parsey, Chief Medical Officer of Gilead Sciences said, "Children living with HIV are in need of effective and accessible formulations of antiretroviral therapy." As children require more treatment options that are readily available on the market, ViiV’s application has great potential in making that happen. ViiV Healthcare CEO, Deborah Waterhouse stated that, “By broadening the treatment options available to children living with HIV, we are one step closer to ending paediatric HIV and AIDs.”